The Citizens Commission on Human Rights (CCHR) today urged consumers to read psychotropic prescription drug labeling for warnings about suicide, aggression, and homicidal ideation, and to ask prescribing physicians to explain those risks even when listed as rare. The call follows news reports of violent crimes in which individuals were reported to be taking or withdrawing from antidepressants, stimulants, or other psychiatric drugs.
CCHR's decades-long campaign has highlighted agitation, aggression, suicidal behavior, and homicidal thoughts linked to some psychotropic drugs. Regulatory agencies in the U.S. and abroad have required warnings on such effects. Jan Eastgate, president of CCHR International, said, "A rare warning buried in a package insert is not the same as a doctor explaining the risk to a patient. Meaningful informed consent requires meaningful disclosure and prescriber accountability."
The issue is also being debated in courtrooms and psychiatric journals. Psychiatric Times recently discussed a murder case where the defense argued psychiatric polypharmacy contributed to violent behavior, concluding that "psychiatry itself may end up on trial." Legal doctrines like involuntary intoxication may apply, but Eastgate noted, "A judge allowing a jury to hear evidence about prescription drugs is not the same as a physician warning a patient before the first dose."
This is not new. In 2004, the FDA issued a public health advisory on antidepressants, and in 2005, Psychiatric Times discussed psychiatrists' duties. CCHR's compilation shows 57 international regulatory warnings since 2004 involving violence, aggression, or hostility—a 1,040% increase—with 13 referencing homicidal ideation. Examples include venlafaxine's labeling added in 2005, bupropion's boxed warning in 2009, stimulants' class-wide warning in 2023, and esketamine's instructions to seek help for aggressive or violent behavior.
For CCHR, the central issue is that printing a warning does not ensure patient awareness. A 2026 Tennessee law requires toxicology testing after violent incidents, and CCHR advocates for similar laws nationwide. Eastgate emphasized, "While not all individuals will become violent or suicidal, they should read these warnings and ask questions before treatment. Prescribers should explain potentially serious side effects and document that the patient was informed."
Ultimately, CCHR stresses that patients should be adequately informed when regulators identify serious behavioral risks, and prescribers must be accountable. Patients should not abruptly stop psychiatric drugs; any changes should be medically supervised. CCHR, established in 1969 by the Church of Scientology and Dr. Thomas Szasz, maintains that transparent disclosure is fundamental to informed consent.
